Search details
1.
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
Hematol Rep
; 16(1): 140-150, 2024 Mar 12.
Article
in English
| MEDLINE | ID: mdl-38534885
2.
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.
Cancers (Basel)
; 15(13)2023 Jun 28.
Article
in English
| MEDLINE | ID: mdl-37444494
3.
Can the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following Induction Therapy?
J Cancer
; 13(4): 1356-1362, 2022.
Article
in English
| MEDLINE | ID: mdl-35281876
4.
Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
World J Clin Oncol
; 11(12): 996-1007, 2020 Dec 24.
Article
in English
| MEDLINE | ID: mdl-33437662
5.
BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia.
Diagnostics (Basel)
; 10(12)2020 Dec 04.
Article
in English
| MEDLINE | ID: mdl-33291851
6.
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations.
Cancers (Basel)
; 12(4)2020 Apr 10.
Article
in English
| MEDLINE | ID: mdl-32290079
Results
1 -
6
de 6
1
Next >
>>